Cutaneous AEs Associated w/ Tyrosine Kinase Inhibitors May Impact QoL & #skincancer treatment Adherence. What next?

Cutaneous Adverse Effects Associated With TKIs Impact Quality of Life and Adherence to Treatment http://t.co/vHgQmlUzgx” #oncodermatology?

— Shaalan Beg (@ShaalanBeg) March 17, 2015